<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Our goal was to determine the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> or non-<z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> associated with paroxysmal compared with sustained <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: The risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and non-<z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> and the efficacy of oral anticoagulation (OAC) in paroxysmal AF as compared with sustained AF are not precisely known </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The ACTIVE W (<z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> <z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> Trial With <z:chebi fb="0" ids="5959">Irbesartan</z:chebi> for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> for prevention of vascular events in 6,706 AF patients </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> and major bleeds were compared in patients with paroxysmal AF (n = 1,202) and persistent or permanent AF (n = 5,495) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with paroxysmal AF were younger, had a shorter AF history, more <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and less valvular disease, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> than patients with sustained AF </plain></SENT>
<SENT sid="5" pm="."><plain>At baseline, patients with paroxysmal AF had a CHADS2 (<z:hpo ids='HP_0001635'>cardiac failure</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, age, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0001297'>stroke</z:hpo> [doubled]) risk score of 1.79 +/- 1.03 compared with 2.04 +/- 1.12 in patients with sustained AF (p &lt; 0.00001) </plain></SENT>
<SENT sid="6" pm="."><plain>The annualized risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> or non-central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> was 2.0 in paroxysmal AF compared with 2.2 in sustained AF (relative risk 0.87, 95% confidence interval [CI] 0.59 to 1.30, p = 0.496) </plain></SENT>
<SENT sid="7" pm="."><plain>After adjusting for confounding baseline variables, the relative risk was 0.94 (95% CI 0.63 to 1.40, p = 0.755) </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of <z:hpo ids='HP_0001297'>stroke</z:hpo> and non-<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> embolism was lower for patients treated with OAC irrespective of type of AF </plain></SENT>
<SENT sid="9" pm="."><plain>There were more <z:mp ids='MP_0001914'>bleedings</z:mp> of any type in patients receiving <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> plus aspirin, irrespective of the type of AF </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Patients with paroxysmal AF treated with aspirin plus <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> or OAC have a similar risk for <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> than patients with sustained AF </plain></SENT>
<SENT sid="11" pm="."><plain>This risk can be significantly lowered with OAC </plain></SENT>
<SENT sid="12" pm="."><plain>(The ACTIVE W trial; http://www.clinicaltrials.gov/ct/show/NCT00243178;NCT00243178) </plain></SENT>
</text></document>